Abstract 2338P
Background
Ovarian cancer (OC) is one of the most common gynecological cancers, with the worst prognosis and the highest mortality rate. According to the FIGO, the overall five-year survival rate is approximately 50%. Tumor-associated macrophages (TAMs) are one of the most prominent populations of immune cells in both ovarian cancer tissue and malignant ascites. The most relevant task is to identify TAM subpopulations in ovarian cancer, to discover how they interact with chemotherapy and affect the development and outcome of the disease.
Methods
Patients with high-grade serous ovarian carcinoma were included in the study. FFPE samples with tumor were obtained after surgery. The study was carried out according to medical ethics. We applied two technologies of spatial transcriptomics for the analysis of TAM transcriptomic features in patients with ovarian cancer – 10x Genomics Visium and Nanostring GeoMX-DSP. All procedures were performed according to manufacturer`s protocols.
Results
The results of 10x Visium demonstrated that TAM cluster express CCL18, APOC1, GPNMB, LYZ, APOE, C1QC, C1QB, CTCB, SPP1, CTSS, and other genes. Interestingly, according to accumulating data the expression of these macrophage markers is distinctive feature for the potentially targeted population of lipid-associated TAMs. The morphology of macrophages in TAM cluster in clinical samples corresponds to the large lipid-associated TAMs. Nanostring technology allowed us to analyse ROIs with immune cells located in different tumor sites. The transcriptome of TAMs located near the tumor nest correlated to functional activation of extracellular matrix organization, antigen presentation, vascular development and myeloid leukocyte activation. These TAMs have the same morphology of large foamy macrophages and express APOE, SPP1, LYZ, CTSS, and other genes.
Conclusions
We found gene signature specific for the large TAMs in tumor tissue of patients with high-grade serous ovarian carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation research project No 21-75-10021.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients
Presenter: Xinyu Wang
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2350P - Single-cell RNA-seq dissecting the initiating liver metastasis cells in various cancers
Presenter: Shu-yue Zheng
Session: Poster session 16
2351P - Whole genome sequencing of AYA patients
Presenter: Paul Roepman
Session: Poster session 16
2352P - Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Presenter: Stefano Cereda
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16